AU2021238643A1 - Ginsenoside compositions - Google Patents

Ginsenoside compositions Download PDF

Info

Publication number
AU2021238643A1
AU2021238643A1 AU2021238643A AU2021238643A AU2021238643A1 AU 2021238643 A1 AU2021238643 A1 AU 2021238643A1 AU 2021238643 A AU2021238643 A AU 2021238643A AU 2021238643 A AU2021238643 A AU 2021238643A AU 2021238643 A1 AU2021238643 A1 AU 2021238643A1
Authority
AU
Australia
Prior art keywords
ginsenosides
composition
increasing
gut microbiota
scfas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021238643A
Other languages
English (en)
Inventor
Pascale Elizabeth Renée FANÇA-BERTHON
Romain LECOZANNET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of AU2021238643A1 publication Critical patent/AU2021238643A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2021238643A 2020-03-20 2021-03-17 Ginsenoside compositions Pending AU2021238643A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2004121.6 2020-03-20
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2005288.2 2020-04-09
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
PCT/EP2021/056803 WO2021185897A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
AU2021238643A1 true AU2021238643A1 (en) 2022-10-20

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021238643A Pending AU2021238643A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions
AU2021238639A Pending AU2021238639A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021238639A Pending AU2021238639A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315264A (https=)
AU (2) AU2021238643A1 (https=)
BR (2) BR112022016241A2 (https=)
CA (2) CA3174698A1 (https=)
WO (2) WO2021185897A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7850670B2 (ja) * 2020-03-20 2026-04-23 ジボダン エス エー ギンセノシド組成物
JP2023161983A (ja) * 2022-04-26 2023-11-08 石川県公立大学法人 サポニンを含む酪酸産生菌増殖能向上組成物、腸内常在菌増殖能向上組成物、乳酸菌増殖能向上組成物及びビフィズス菌増殖能向上組成物
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706B (zh) * 2023-12-20 2025-10-14 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
SG11202000258TA (en) 2017-07-18 2020-02-27 Senescence Life Sciences Pte Ltd Compositions and methods for the treatment and prevention of cognitive decline and preservation of neuronal function
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用
JP7850670B2 (ja) 2020-03-20 2026-04-23 ジボダン エス エー ギンセノシド組成物

Also Published As

Publication number Publication date
CN115315266A (zh) 2022-11-08
JP7850670B2 (ja) 2026-04-23
CA3174699A1 (en) 2021-09-23
WO2021185890A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
BR112022016241A2 (pt) 2022-10-11
JP2023518064A (ja) 2023-04-27
BR112022015826A2 (pt) 2022-10-04
US20230124503A1 (en) 2023-04-20
AU2021238639A1 (en) 2022-09-15
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
CA3174698A1 (en) 2021-09-23
WO2021185897A1 (en) 2021-09-23
JP2023519189A (ja) 2023-05-10
CN115315264A (zh) 2022-11-08
JP7808042B2 (ja) 2026-01-28

Similar Documents

Publication Publication Date Title
US20230124503A1 (en) Ginsenoside compositions
Tian et al. Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation
Chen et al. Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice
Chen et al. Ginsenoside Rb1 exerts neuroprotective effects through regulation of Lactobacillus helveticus abundance and GABAA receptor expression
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
JP5204771B2 (ja) Ｇａｂａ作動性ニューロン賦活剤
Martirosyan et al. The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders
Campaniello et al. A narrative review on the use of probiotics in several diseases. Evidence and perspectives
CN102242152B (zh) 腐植酸活性组分、其制备方法、应用及含其的药物组合物
US20210121505A1 (en) Compositions and methods for treating inflammatory bowel diseases
Florina et al. The Interdependence between diet, microbiome, and human body health-a systemic review
JP7514926B2 (ja) 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用
US20210205397A1 (en) Methods for supporting weight loss and weight loss maintenance by administration of aquatic plants and/or autologous microbiome samples
Gangzheng et al. Effect and correlation of Cordyceps guangdongensis ethanolic extract on obesity, dyslipidemia and gut microbiota dysbiosis in high-fat diet mice
Yang et al. The regulatory effects of Lonicera japonica flos on fecal microbiota from humans with type 2 diabetes in a SHIME model
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
Tampanna et al. The role of kratom (Mitragyna speciosa Korth.) extract in medical foods for obese patients: Effects on gut microbiota in a colon model
Yang et al. The short-term and long-term effects of Dendrobium officinale leaves polysaccharides on the gut microbiota differ
TWI810645B (zh) 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
WO2023000408A1 (zh) 包含β-烟酰胺单核苷酸和刺梨提取物的组合物及其应用
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
WO2026078116A1 (en) Substances for use as a prebiotic or as a medicine
JP2021195326A (ja) 腸内菌叢改善用組成物
EP3370751A1 (en) Lentil extract with cholesterol lowering and prebiotic activity